RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • Measuring the Value of Therapies for Ultra-Rare Diseases
    The pricing of drugs is characterized by a tension between providing incentives to drug companies to invest in the development of innovative therapies and ensuring affordability so patients have access to needed medicines. The Institute for Clinical and Economic Review, an independent non-profit research institute that analyzes the evidence on the effectiveness and value of drugs and other medical services, recently issued final modifications to its framework for assessing the value of treatments for serious, ultra-rare diseases. The framework applies to therapies that are eligible to treat no more than 10,000 U.S. patients including certain treatments for inherited eye disease, hemophilia A, and cystic fibrosis. We spoke to Steven Pearson, president of ICER, about the framework, why modifications were needed for drugs to treat ultra-rare diseases, and what the implications are for a pipeline or therapies with the potential not just to treat, but to cure progressive and deadly rare diseases.
    25 min
  • Lessons from Pitching Venture Capitalists
    Stories abound about plucky entrepreneurs financing their startups, but it’s unusual to get trench-view insights from founders who have slogged their way through endless pitches along Sand Hill Road. Ethan Perlstein, founder and CEO of the rare disease drug discovery company Perlara, shared what he gleaned from his recent $7.4 million equity round for his company in a piece on the CNBC website. We spoke to Perlstein about his experience, what he learned in the process, and his practical advice for entrepreneurs seeking funding.
    21 min
  • Health Canada Scraps Plans for Orphan Drug Framework
    Health Canada has derailed a long-fought effort to establish a framework for orphan drugs. Last month the agency, without warning, removed from its website all documents relating to the effort. The agency says its conducting a broader review of regulations and will now seek to address the aims of the orphan drug framework through other means. The decision is a blow to rare disease advocates in Canada, who view the move as a response to provincial governments who feared an orphan drug designation would be a license to charge high prices for medications. We spoke Durhane Wong-Rieger, president and CEO of The Canadian Organization for Rare Disorders, about the Health Canada’s unexpected decision, why an orphan drug framework is seen as critical to making needed therapies available in Canada, and what it means for the rare patient community there.
    20 min
  • New Investment Boosts Rare Disease Drug Accelerator
    Cydan, an orphan drug accelerator focused on developing therapies for rare genetic diseases, recently completed a $34 million financing round. With a core team that seeks to in-license promising experimental therapies, Cydan conducts preclinical development in-house and then, should circumstances warrant, spins out a company to conduct clinical development of promising assets. It’s first company Vtesse, which is developing drug for Niemann-Pick Disease Type C, has already been acquired. Its second company, Imara, is developing a treatment for sickle cell disease. We spoke to Chris Adams, CEO of Cydan, about its business model, how it differs from other similar approaches, and whether it provides a faster and cheaper way to get therapies to market.
    23 min
  • Understanding Rare Disease Caregiver Needs
    Rare disease caregivers are good at advocating for their family members, for research, and for the needs of rare disease patients broadly. What they often fail to do, though, is advocate for themselves. The National Alliance for Caregiving, in partnership with Global Genes, is conducting a first-of-its-kind study of rare disease caregivers to better understand the challenges they face and determine whether there are common issues they share that may warrant policy changes. We spoke to Grace Whiting, Interim CEO and Chief Operating Officer of the National Alliance for Caregiving, about the study, what the organizations are hoping to determine, and how the findings will be used.
    19 min
  • Deriving Rare Disease Therapies from Human Plasma
    Prometic Life Sciences is developing both plasma-derived and small molecule therapeutics to address a number of rare diseases that are today without therapies. Its lead experimental therapeutic is Ryplazim, which is purified human plasminogen that is being developed to treat congenital plasminogen deficiency. Plasminogen is a naturally occurring protein that plays a critical role in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis. We spoke to Pierre Laurin, president and CEO of Prometic, about Ryplazim, the challenges and benefits of deriving products from human plasma, and what else is moving through the company’s pipeline.
    19 min
  • Learning to Live with Purpose
    Claire Wineland has defied the odds. At 20, she’s lived more than twice as long as doctors told her parents she would. Born with cystic fibrosis, Wineland has spent about a quarter of her life in hospitals, and her daily health regimen is a demanding routine of treatments, medications, and oxygen. Despite her health problems, though, she has learned to find purpose by helping others. At the age of 13 she founded Claire’s Place Foundation to provide support to CF patients and their families. She’s also touched many others with her YouTube videos and public talks where she speaks about her illness and dying, with charm, humor, and a life-affirming wisdom. We spoke to Wineland, a 2017 Global Genes’ Champion of Hope awardee, about her life with cystic fibrosis, what its taught her about living, and how finding a greater purpose than treating her own illness transformed her life.
    40 min
  • A Mother's Race to Find a Treatment for Her Daughter's Ultra-Rare Condition
    When Amber Olsen’s daughter Willow was diagnosed in 2016 with an ultra-rare lysosomal storage disorder known as multiple sulfatase deficiency, the diagnosis was grim. There is no treatment for the disease and most children with the condition don’t live past the age of 10. Unlike other lysosomal storage disorders that have been treated with enzyme replacement therapies, MSD involves a lack of multiple enzymes. It also includes significant central nervous system involvement that makes delivery of therapies that much more challenging. We spoke to Olsen about MSD, the United MSD Foundation she founded to drive research toward treatments, and how she enlisted one researcher to pursue a potential gene therapy.
    20 min
  • Screening for Rare Diseases
    Disorder: The Rare Disease Film Festival will debut in Boston October 2 and 3 featuring a range of more than 30 films focused on topics of rare disease. The event will also include talks from filmmakers, patient advocates, and researchers as the organizers not only hopes to raise awareness about rare diseases, but also begin conversations and forge connections. We spoke to Bo Bigelow, one of the organizers of the event, about the film festival, his own search for answers about his daughter’s ultrarare condition, and why this festival is about more than just the films themselves.
    21 min
  • A Look at the Changing World of Work for People with a Chronic Illness
    People with a chronic illness may be able to work, but commuting to a 9-to-5 job in an office might not be ideal. Chronically Employed (http://chronicallyemployed.com/) is a new website that offers job listings, career advice, and stories for people who continue in their careers after a diagnosis. We spoke to Ilana Jacqueline, editor-in-chief of Chronically Employed, about the new site, the changing view of employers toward work-at-home employees, and the growing opportunities for jobseekers with a chronic illness.
    16 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.